Evidence map›Paper›PMID 36960655›Full record

ArticlePediatrics2023

Influenza Vaccine Effectiveness Among Children: 2011-2020.

Nicole Hood, Brendan Flannery, Manjusha Gaglani, Madhava Beeram, Karen Wernli, Michael L Jackson, Emily T Martin, Arnold S Monto, Richard Zimmerman, Jonathan Raviotta and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Observational
  2. Influenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024-25 season.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  3. Article
  4. Article
  5. Analysis of influenza A, influenza B andFrontiers in public health · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Nicole HoodInfluenza Division, US Centers for Disease Control and Prevention, Atlanta, Georgia.
Brendan FlanneryInfluenza Division, US Centers for Disease Control and Prevention, Atlanta, Georgia.
Manjusha GaglaniTexas A&M University Health Science Center College of Medicine, Temple, Texas.
Madhava BeeramTexas A&M University Health Science Center College of Medicine, Temple, Texas.
Karen WernliKaiser Permanente Washington Health Research Institute, Seattle, Washington.
Michael L JacksonKaiser Permanente Washington Health Research Institute, Seattle, Washington.
Emily T MartinSchool of Public Health, University of Michigan, Ann Arbor, Michigan.
Arnold S MontoSchool of Public Health, University of Michigan, Ann Arbor, Michigan.
Richard ZimmermanSchool of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Jonathan RaviottaSchool of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Edward A BelongiaMarshfield Clinic Research Institute, Marshfield, Wisconsin.
Huong Q McLeanMarshfield Clinic Research Institute, Marshfield, Wisconsin.
Sara KimInfluenza Division, US Centers for Disease Control and Prevention, Atlanta, Georgia.
Manish M PatelInfluenza Division, US Centers for Disease Control and Prevention, Atlanta, Georgia.
Jessie R ChungInfluenza Division, US Centers for Disease Control and Prevention, Atlanta, Georgia.
Centers for Disease Control and Prevention · USBaylor Scott & White Health · USKaiser Permanente Washington Health Research Institute · USMarshfield Clinic · USUniversity of Michigan · USUniversity of Pittsburgh · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE: BPCAUL1RR024153 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2006 to 2011
$73.9M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
US Influenza Vaccine Effectiveness NetworkU01IP001034 · IP · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MONTO, ARNOLD S · 2016 to 2020
$10.0M
Annual Estimates of Influenza Vaccine Effectiveness and Evaluation of Immune Response in a Wisconsin PopulationU01IP001038 · IP · MARSHFIELD CLINIC RESEARCH FOUNDATION · PI BELONGIA, EDWARD · 2016 to 2020
$8.0M
Prospective annual estimates of influenza vaccine effectiveness and burden of diseaseU01IP001037 · IP · KAISER FOUNDATION RESEARCH INSTITUTE · PI JACKSON, MICHAEL L · 2016 to 2020
$7.8M
Outpatient VE for seasonal flu, pandemic flu and RSV in a large, diverse networkU01IP001035 · IP · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZIMMERMAN, RICHARD K · 2016 to 2020
$7.8M
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.U01IP001039 · IP · SCOTT AND WHITE MEMORIAL HOSPITAL · PI GAGLANI, MANJUSHA · 2016 to 2020
$6.5M
Core_plus_Option_A_B_Proposal for Influenza Vaccine Effectiveness ResearchU01IP000474 · IP · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MONTO, ARNOLD S · 2011 to 2015
$6.2M
Core_plus Option_A_C_Influenza Surveillance and Vaccine Effectiveness in a LargeU01IP000467 · IP · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZIMMERMAN, RICHARD K · 2011 to 2015
$5.9M
Core_plus Option_B_C_Influenza Vaccine Effectiveness in a Wisconsin PopulationU01IP000471 · IP · MARSHFIELD CLINIC RESEARCH FOUNDATION · PI BELONGIA, EDWARD · 2011 to 2015
$5.6M
Core_Prospective population-based estimation of influenza vaccine effectiveness aU01IP000466 · IP · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI JACKSON, MICHAEL L · 2011 to 2015
$4.1M
ACL HHS U01IP000473ACL HHS U01IP001034ACL HHS U01IP001035ACL HHS U01IP001037ACL HHS U01IP001038ACL HHS U01IP001039NCATS NIH HHS UL1 TR000005NCATS NIH HHS UL1 TR001857NCIRD CDC HHS U01 IP000466NCIRD CDC HHS U01 IP000467NCIRD CDC HHS U01 IP000471NCIRD CDC HHS U01 IP000473NCIRD CDC HHS U01 IP000474NCIRD CDC HHS U01 IP001034NCIRD CDC HHS U01 IP001035NCIRD CDC HHS U01 IP001037NCIRD CDC HHS U01 IP001038NCIRD CDC HHS U01 IP001039NCRR NIH HHS UL1 RR024153
6 · The paper itself

Abstract

BACKGROUND AND

objectivesInfants and children are at increased risk of severe influenza virus infection and its complications. Influenza vaccine effectiveness (VE) varies by age, influenza season, and influenza virus type/subtype. This study's objective was to examine the effectiveness of inactivated influenza vaccine against outpatient influenza illness in the pediatric population over 9 influenza seasons after the 2009 A(H1N1) pandemic.

methodsDuring the 2011-2012 through the 2019-2020 influenza seasons at outpatient clinics at 5 sites of the US Influenza Vaccine Effectiveness Network, children aged 6 months to 17 years with an acute respiratory illness were tested for influenza using real-time, reverse-transcriptase polymerase chain reaction. Vaccine effectiveness was estimated using a test-negative design.

resultsAmong 24 148 enrolled children, 28% overall tested positive for influenza, 3017 tested positive for influenza A(H3N2), 1459 for influenza A(H1N1)pdm09, and 2178 for influenza B. Among all enrollees, 39% overall were vaccinated, with 29% of influenza cases and 43% of influenza-negative controls vaccinated. Across all influenza seasons, the pooled VE for any influenza was 46% (95% confidence interval, 43-50). Overall and by type/subtype, VE against influenza illness was highest among children in the 6- to 59-month age group compared with older pediatric age groups. VE was lowest for influenza A(H3N2) virus infection.

conclusionsAnalysis of multiple seasons suggested substantial benefit against outpatient illness. Investigation of host-specific or virus-related mechanisms that may result in differences by age and virus type/subtype may help further efforts to promote increased vaccination coverage and other influenza-related preventative measures.

Indexed as

Influenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesCase-Control StudiesChildChild, PreschoolHumansInfantInfluenza A Virus, H3N2 SubtypeInfluenza B virusSeasonsVaccinationVaccine EfficacyVaccines, InactivatedInfluenza VaccinesVaccines, Inactivated

Identifiers

PMID36960655
PMCPMC10071433
OpenAlexW4360814548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.